Total remission of severe immune thrombocytopenia after short term treatment with romiplostim

Hematology Reports

Volumn 3, Issue 3, 2011, Pages 58-59

  Vlachaki, Efthymia ^a   Papageorgiou, Vaia ^a   Klonizakis, Filippos ^a   Spandonidou, Maria ^a   Chisan, Sofia ^a   Vetsiou, Evaggelia ^a   Ioannidou, Elissavet ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Immune thrombocytopenia; Romiplostim; Throm bopoietin receptor agonists

Indexed keywords

EID: 84923077266     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2011.e20     Document Type: Article

References (15)

1. Provan D, Stasi R, Newland A, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168-86.
2. Cuker A, Cines DB. Immune thrombocy-topenia. Hematology Am Soc Hematol Educ Program 2010;2010:377-84.
3. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, defini-tions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93.
4. Neylon A, Saunders P, Howard M, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. B J Haematol 2003;122:966-74.
5. Stasi R, Evangelista M, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and man-agement. Thromb Haemost 2008;99:4-13.
6. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol 2007;44Suppl5:S3-S11.
7. De Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533-8.
8. Kaushansky K, Lok S, HollY R, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369:568-71.
9. Mukai H, Kojima H, Todokoro K, et al. Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocy-topenia are much higher than those with immune thrombocytopenic purpura. Thromb Haemost.1996;76:675-8.
10. Andemariam B, Psaila B, Bussel J. Novel thrombopoietic agents. Hematol Am Soc Hematol Educ Program 2007;106-13.
11. Cersosimo R. Romiplostim in chronic immune thrombocytopenic purpura. Clin Ther 2009;31:1887-907.
12. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpu-ra: a double-blind randomised controlled trial. Lancet 2008;371:395-403.
13. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355: 1672-81.
14. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evi-dence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190-207.
15. Pohlen M, Sargin B, Zicholl S, et al. Combination of romiplostim and ritux-imab: effective therapy of severe immune thrombocytopenia. Eur J Haematol 2010; 84:362-4.